Discontinued — last reported Q4 '25

Investing

Acquisitions

Cintas Acquisitions decreased by 89.0% to $9.45M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 78.5%, from $43.92M to $9.45M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 119.5% CAGR.

Analysis

StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025

How to read this metric

High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.

Detailed definition

This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...

Peer comparison

Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.

Metric ID: acquisitions

Historical Data

20 periods
 Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$2.47M$35.73M$9.95M$105.17M$13.38M$7.06M$8.40M$17.53M$13.37M$55.65M$18.35M$111.03M$1.81M$9.44M$145.45M$43.92M$34.09M$7.60M$85.63M$9.45M
QoQ Change>999%-72.2%+957.6%-87.3%-47.3%+18.9%+108.7%-23.7%+316.1%-67.0%+505.2%-98.4%+421.6%>999%-69.8%-22.4%-77.7%>999%-89.0%
YoY Change+442.3%-80.2%-15.6%-83.3%-0.1%+688.3%+118.5%+533.5%-86.5%-83.0%+692.8%-60.4%>999%-19.4%-41.1%-78.5%
Range$1.81M$145.45M
CAGR+32.7%
Avg YoY Growth+232.0%
Median YoY Growth-17.5%

Frequently Asked Questions

What is Cintas's acquisitions?
Cintas (CTAS) reported acquisitions of $9.45M in Q4 2025.
How has Cintas's acquisitions changed year-over-year?
Cintas's acquisitions decreased by 78.5% year-over-year, from $43.92M to $9.45M.
What is the long-term trend for Cintas's acquisitions?
Over 4 years (2021 to 2025), Cintas's acquisitions has grown at a 119.5% compound annual growth rate (CAGR), from $10.04M to $232.90M.
What does acquisitions mean?
Cash spent to acquire other companies or businesses, net of cash received in the deal.